AstraZeneca PLC (AZN)
NYSE • Healthcare
February 17, 2026 at 21:00 UTC
Name
CEO
Website
Industry
Year Founded
Employees
AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and supplies medicines used in hospitals and clinics around the world. The operating idea is steady and practical: move research through development, manufacture to consistent standards, and support appropriate use with clear guidance for clinicians. Programs focus on conditions that require long-term treatment and careful monitoring, so labeling, education, and supply planning sit close to scientific work. Country teams adapt access and information to local frameworks while holding to common safety principles. The purpose is to turn complex science into options that fit daily care, with availability that health systems can plan around rather than chase.
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
AstraZeneca PLC's Technical Indicators Summary
AZN demonstrates a bullish trend as its current price hovers just above key short- and medium-term moving averages, which themselves sit well above the 200-day averages, indicating sustained upward momentum. The MACD and momentum indicators support this positive bias, reflecting growing buying strength. Although the ADX suggests moderate trend strength, it does not yet signal a strong directional move, while volatility remains steady with the ATR showing limited price fluctuations. The on-balance volume confirms accumulation, reinforcing the overall positive sentiment. Despite some oscillators signaling caution or neutrality, the alignment of price above critical moving averages alongside supportive momentum and volume metrics underscores a constructive technical posture for AZN.
| Indicator | Value |
|---|---|
RSI (14) | 56.71 |
Stochastic %K (14, 3, 3) | 77.03 |
CCI (20) | 53.99 |
WPR (14) | -30.37 |
Momentum (10) | 2.82 |
MFI | 21.94 |
MACD Level (12, 26) | 1.20 |
Bollinger Bands | $89.97 - $96.27 |
ATR (14) | $1.73 (1.84%) |
ADX (14) | 21.05 |
OBV | 202,330,200 |
Simple Moving Averages | $78.81 - $94.29(5 indicators) |
Exponential Moving Averages | $81.10 - $94.14(5 indicators) |
Get premium market insights delivered directly to your inbox.
The day wrapped with AZN preserving a mild 1.712% upside gap, closing near 209.07. End-of-day, the peer group was roughly unchanged (-0.16%), limiting broader influence on AZN. AZN edges higher amid legal wins and positive clinical trial results, with supportive investor sentiment.
Price Change
from $205.55 close
+$3.52
Trading Volume
Below avg (3.1M)
2.1M
vs S&P 500 Today
Strong Outperformance
+3.37%
52-Week Position
Near highs
97.5%
Updated: February 17, 2026 at 21:02 UTC
Moderna, Mexico sign mRNA vaccine pact
February 11, 2026